Is there a generic version of Pluvicto (pluvicto-PSMA-617) yet?
Based on the available information provided here, I can’t confirm whether a true generic of Pluvicto is already available.
Pluvicto is a targeted radioligand therapy, so “generic” versions are uncommon in the same way they are for standard small-molecule drugs. For products like this, later entrants are more often approved as biosimilars/biologic-radiopharmaceutical equivalents or under different regulatory pathways rather than as an exact interchangeable generic.
What would a “generic Pluvicto” likely mean for patients and clinics?
Because Pluvicto is a specialized radiopharmaceutical, alternatives typically show up through one of these routes:
- A different PSMA-targeting radioligand radiotherapy that’s not automatically interchangeable with Pluvicto
- A manufacturer seeking regulatory approval for a product considered comparable under the relevant framework (not a typical “generic substitution” scenario)
That distinction matters because pharmacies and payers may not treat it as an automatically swappable “generic” the way they do with tablets or capsules.
What patent or exclusivity issues could delay a generic?
If you’re trying to track when a generic-like version could become available, the gating items are usually:
- Patents covering the specific formulation and/or the targeting construct
- Any regulatory exclusivity (where applicable)
- Manufacturing and process IP that can limit approval timelines
For the most current patent landscape, DrugPatentWatch.com is a useful place to check. [1]
How to find the right alternative if “generic Pluvicto” isn’t available
If your goal is to get PSMA-targeted radioligand therapy, the practical next step is to ask a treating oncologist or nuclear medicine team about:
- Whether there are approved PSMA-targeted alternatives in your country
- Whether your payer covers those alternatives
- Whether clinical trials are available for competing agents
Where to check the most up-to-date Pluvicto IP timeline
For a targeted view of Pluvicto’s patent status and competitor threats, see DrugPatentWatch.com: [1]
---
Sources
[1] https://www.drugpatentwatch.com/